1.58
+0.14(+9.72%)
Currency In USD
| Previous Close | 1.44 |
| Open | 2.45 |
| Day High | 2.67 |
| Day Low | 1.54 |
| 52-Week High | 3.26 |
| 52-Week Low | 1.12 |
| Volume | 82.78M |
| Average Volume | 1.41M |
| Market Cap | 16.19M |
| PE | -1.27 |
| EPS | -1.24 |
| Moving Average 50 Days | 1.61 |
| Moving Average 200 Days | 1.72 |
| Change | 0.14 |
If you invested $1000 in Cocrystal Pharma, Inc. (COCP) 10 years ago, it would be worth $6.27 as of September 14, 2025 at a share price of $1.58. Whereas If you bought $1000 worth of Cocrystal Pharma, Inc. (COCP) shares 5 years ago, it would be worth $137.15 as of September 14, 2025 at a share price of $1.58.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
GlobeNewswire Inc.
Sep 12, 2025 1:43 PM GMT
$4.7 million upfront with up to an additional approximately $8.3 million of potential aggregate gross proceeds upon the exercise in full of warrants BOTHELL, Wash., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc., (Nasdaq: COCP) (the “Com
Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference
GlobeNewswire Inc.
Sep 12, 2025 12:00 PM GMT
BOTHELL, Wash., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that President and co-CEO Sam Lee, PhD discussed the scientific foundation and clinical progress with the Company’s lead pan-viral protease inhibitor
Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment
GlobeNewswire Inc.
Sep 08, 2025 12:00 PM GMT
There are currently no approved vaccines or treatments for norovirus infectionCocrystal’s CDI-988 is the first antiviral for the potential prevention and treatment of viral gastroenteritis caused by norovirus infections Phase 1b study is expected to